Analysis of the cardiovascular effects of co-derocrine (Hydergine)
- PMID: 2869189
Analysis of the cardiovascular effects of co-derocrine (Hydergine)
Abstract
The antihypertensive effect of co-dergocrine (Hydergine) has previously been thought to be due to alpha-adrenoceptor blockade and/or an action exerted in the CNS. The present experiments do not support this view. The doses necessary to inhibit vasoconstrictor responses to phenylephrine and noradrenaline by 50% in anaesthetized cats and dogs are 10-50 times that which lowers blood pressure in these species by 30 mmHg. Despite the fact that co-dergocrine is a potent alpha-adrenoceptor antagonist in isolated tissues (pA2: 8.4-9.4), its activity in vivo is too weak to contribute significantly to its effect on blood pressure. Slow intravertebral artery infusion of 10 micrograms/kg co-dergocrine produces a smaller blood pressure fall in the dog than intravenous infusion of the same dose. The reverse is true for the centrally-acting alpha 2-adrenoceptor stimulant, guanfacine. In addition, efferent splanchnic nerve activity in the cat is not affected by doses up to 100 micrograms/kg i.v. The dose of co-dergocrine depressing nerve activity by 50% is approximately 900 micrograms/kg; the dose of clonidine producing comparable inhibition is 3.4 micrograms/kg i.v. Since falls in blood pressure and heart rate can be obtained with co-dergocrine at a dose of only 10 micrograms/kg i.v., a central action cannot be considered to play a role in the cardiovascular effects of the drug in response to acute administration. Heart rate increases evoked by stimulating the accelerans nerve of ganglion-blocked cats are inhibited dose-dependently by co-dergocrine from a dose of 1 microgram/kg i.v. The drug also depresses pressor responses to stimulation of the lumbar sympathetic outflow in pithed rats. Both effects are prevented by pretreatment with the dopamine receptor antagonist, sulpiride (300 micrograms/kg). Intravenous administration of 10 micrograms/kg co-dergocrine depresses pressor responses to a psychological stimulus or raising the forequarters in conscious dogs, and produces marked falls in blood pressure and heart rate in anaesthetized, baroreceptor-denervated dogs. These effects are also abolished by sulpiride. It is concluded that the cardiovascular responses to acute administration of low doses of co-dergocrine are due to stimulation of prejunctional dopamine receptors.
Similar articles
-
Pharmacological, hemodynamic and biochemical mechanisms involved in the blood pressure lowering effects of pergolide, in normotensive and hypertensive dogs.J Pharmacol Exp Ther. 1985 Dec;235(3):798-809. J Pharmacol Exp Ther. 1985. PMID: 2934543
-
Pharmacological actions of the antihypertensive agent N-amidino-2-(2,6-dichlorophenyl)acetamide hydrochloride (BS 100-141).Arzneimittelforschung. 1975 Oct;25(10):1483-91. Arzneimittelforschung. 1975. PMID: 1243025
-
Pharmacological, hemodynamic and autonomic nervous system mechanisms responsible for the blood pressure and heart rate lowering effects of pergolide in rats.J Pharmacol Exp Ther. 1984 Mar;228(3):779-91. J Pharmacol Exp Ther. 1984. PMID: 6707926
-
Hydergine: interaction with the neurotransmitter systems in the central nervous system.J Pharmacol. 1985;16 Suppl 3:1-17. J Pharmacol. 1985. PMID: 2869188 Review. English, French.
-
Is stimulation of prejunctional dopamine receptors an antihypertensive principle?Clin Exp Hypertens A. 1987;9(5-6):1045-68. doi: 10.3109/10641968709161465. Clin Exp Hypertens A. 1987. PMID: 3304728 Review.
Cited by
-
Co-dergocrine mesylate inhibits the increase in plasma catecholamines caused by nifedipine in essential hypertension.Eur J Clin Pharmacol. 1990;39(5):435-9. doi: 10.1007/BF00280932. Eur J Clin Pharmacol. 1990. PMID: 2076734 Clinical Trial.
-
Reversal by the selective D-2 dopamine receptor blocker sulpiride of the hypotensive effect of co-dergocrine in elderly hypertensives.Eur J Clin Pharmacol. 1987;33(5):519-21. doi: 10.1007/BF00544247. Eur J Clin Pharmacol. 1987. PMID: 2962878 Clinical Trial.
-
Inhibition of the aldosterone response to sodium depletion in man by stimulation of dopamine DA2 receptors.Eur J Clin Pharmacol. 1988;35(3):323-6. doi: 10.1007/BF00558273. Eur J Clin Pharmacol. 1988. PMID: 2972550 Clinical Trial.
-
Clinical pharmacokinetics of the nifedipine/co-dergocrine combination in impaired liver and renal function.Eur J Drug Metab Pharmacokinet. 1992 Jan-Mar;17(1):33-8. doi: 10.1007/BF03189985. Eur J Drug Metab Pharmacokinet. 1992. PMID: 1499595
MeSH terms
Substances
LinkOut - more resources
Miscellaneous